CAR T-Cell Therapy Market Intelligence Master Dataset, Competitive Quadrant and Dashboard

The CAR T-cell therapy market includes pharmaceutical companies, biotechnology developers, and specialized manufacturers competing to develop and commercialize cell-based cancer treatments.

Key companies include:

• Gilead Sciences / Kite Pharma: Commercializes Yescarta and other cell therapies.

• Johnson & Johnson / Legend Biotech: Commercializes Carvykti for multiple myeloma.

• Bristol Myers Squibb: Commercializes Breyanzi and Abecma.

• Novartis: Commercializes Kymriah and develops cell therapy capabilities.

• Lonza: Provides specialized development and manufacturing services.

• Allogene Therapeutics, Curocell, and JW Therapeutics: Participate in the CAR T-cell development and commercialization landscape.

  Explore our CAR T-Cell Therapy Market research and request a customized sample: https://www.towardshealthcare.com/download-sample/5028 

These companies face different business priorities. Established pharmaceutical companies need to strengthen their portfolios and commercial positions, while emerging biotech companies must demonstrate clinical differentiation, secure funding, and establish manufacturing or commercialization partnerships.

Towards Healthcare Research & Consulting studies these competitive dynamics to help pharmaceutical leaders, biotech executives, investors, and business development teams evaluate opportunities using structured market and company intelligence.

What Towards Healthcare Has Researched?

During our research into the CAR T-cell therapy market, Towards Healthcare assessed market size, growth forecasts, regional performance, drug types, therapeutic indications, and end-user segments.

According to the supplied Towards Healthcare source, the global market was valued at US$12.88 billion in 2025 and is projected to reach US$193.6 billion by 2035. The source estimates a market size of US$16.23 billion in 2026 and a compound annual growth rate (CAGR) of 29.80% from 2026 to 2035.

The research identifies North America as the leading region in 2025, while Asia-Pacific is expected to record the fastest growth. Axicabtagene ciloleucel leads by drug type, and lymphoma leads by indication, according to the source.

Source: Towards Healthcare CAR T-Cell Therapy Research.

These figures indicate the potential scale of the opportunity, but companies need more than an overall forecast to make investment and expansion decisions. They need to understand which segments are growing, which competitors hold strong positions, and where unmet business needs create opportunities.

Key Segments in the CAR T-Cell Therapy Market

Towards Healthcare's research examines the following market segments:

• By drug type: Axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others.

• By indication: Lymphoma, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and others.

• By end user: Hospitals and cancer treatment centers.

• By region: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

These segments help companies assess commercial opportunities, prioritize indications, evaluate regional expansion, and identify areas for further research.

For example, a biotech company developing a new CAR T-cell candidate may need to compare competing therapies within its target indication. A CDMO may want to assess manufacturing demand and potential clients. An investor may focus on pipeline differentiation, partnerships, and commercial prospects.

Towards Healthcare connects market segmentation with company-level intelligence to support these different business requirements.

CAR T-Cell Therapy Master Dataset by Towards Healthcare

Market forecasts explain the potential size of an opportunity. A master dataset helps decision-makers investigate the companies, therapies, investments, and competitive developments behind that opportunity.

Towards Healthcare develops market intelligence to support structured research and business planning. For the CAR T-cell therapy market, a relevant master dataset can include:

• Company profiles: Pharmaceutical companies, biotech developers, and cell therapy manufacturers.

• Product intelligence: Commercial therapies, drug types, target indications, and company portfolios.

• Pipeline intelligence: Clinical-stage candidates, development progress, therapeutic targets, and milestones.

• Deal intelligence: Licensing agreements, acquisitions, investments, and strategic partnerships.

• Manufacturing intelligence: CDMOs, facility locations, manufacturing capabilities, and regional developments.

• Commercial intelligence: Market forecasts, regional opportunities, segment performance, and competitor positioning.

This dataset can help a pharmaceutical company benchmark its portfolio, a biotech founder identify potential partners, or an investor compare companies before conducting detailed due diligence.

The objective is to make relevant information easier to organize, compare, and use in business decisions.

Access detailed CAR T-Cell Therapy Market insights to support your business decisions: https://www.towardshealthcare.com/checkout/5028 

Competitive Quadrant for CAR T-Cell Therapy Companies

Companies need a clear view of their competitors before making decisions about product development, partnerships, or market entry.

Towards Healthcare's competitive quadrant approach can help assess companies using defined criteria such as:

• Commercial product presence and portfolio breadth

• Clinical pipeline depth and development progress

• Manufacturing capabilities and commercialization presence

• Partnerships, geographic coverage, and strategic positioning

For example, Gilead Sciences, Johnson & Johnson, Bristol Myers Squibb, and Novartis can be assessed alongside emerging biotech companies. CDMOs such as Lonza require a separate framework because their business models differ from those of therapy developers.

A well-defined quadrant helps pharmaceutical strategy teams benchmark competitors, business development teams identify potential partners, and investors compare companies against relevant criteria.

Company placement should rely on verified data and a transparent scoring methodology rather than unsupported rankings.

Dedicated Cell and Gene Therapy Dashboard

CAR T-cell therapy falls within the broader cell and gene therapy category. A dedicated dashboard for this category can help users organize relevant company, pipeline, competitive, and market intelligence in one place.

Towards Healthcare's dashboard access can be explored for business intelligence requirements. Depending on the selected offering, relevant research areas may include:

• Market size, forecasts, and segment analysis

• Company portfolios and competitive developments

• Clinical pipeline and therapeutic indications

• Partnerships, investments, and licensing activity

• Manufacturing capabilities and regional opportunities

• Competitor benchmarking and strategic planning

For pharmaceutical companies, this intelligence can support portfolio planning. For biotechnology developers, it can inform competitive assessments and partnership research. For investors, it can provide a structured starting point for company comparisons and further due diligence.

Explore Towards Healthcare Dashboard Access to discuss your requirements. Specific features and datasets depend on the selected dashboard and access package.

CAR T-Cell Therapy Market Challenges and Solutions

1. Manufacturing capacity and production complexity

CAR T-cell therapies require specialized manufacturing, quality controls, and, for autologous treatments, patient-specific production. These requirements can create operational bottlenecks.

How Towards Healthcare helps: Manufacturing intelligence, CDMO research, facility benchmarking, and company datasets can support the assessment of production capabilities and potential partners.

2. Treatment costs and patient access

High treatment costs, specialized care requirements, and reimbursement challenges can limit access to CAR T-cell therapies.

How Towards Healthcare helps: Regional analysis, segment intelligence, and strategic consulting can help companies assess commercial barriers and evaluate geographic opportunities.

3. Competition and pipeline differentiation

Established pharmaceutical companies and emerging biotech developers compete across therapeutic indications, clinical programs, and treatment approaches.

How Towards Healthcare helps: A master dataset and competitive quadrant can support portfolio comparisons, pipeline benchmarking, and the identification of potential competitive gaps.

4. Partnership and commercialization decisions

Companies must evaluate licensing opportunities, manufacturing partners, clinical collaborators, and potential markets for expansion.

How Towards Healthcare helps: Partnership intelligence, buyer identification, competitor tracking, and GTM strategy research can help organizations prioritize relevant opportunities.

These services provide research and strategic decision support. They do not replace clinical, regulatory, or investment due diligence.

What Towards Healthcare Research & Consulting Can Provide

Towards Healthcare connects market research with company-level intelligence to help pharmaceutical companies, biotech developers, CDMOs, investors, and business development teams make better-informed decisions.

Our relevant research and consulting capabilities include:

• Complete Master Dataset: Organized company, product, pipeline, and commercial intelligence.

• Competitive Quadrant: Evidence-based competitor comparisons and positioning.

• Customized Dashboard: Relevant intelligence organized around your research and business requirements.

• Pipeline Intelligence: Clinical development tracking and therapy-level comparisons.

• Buyer Identification: Research to identify relevant potential customers, partners, and business stakeholders.

• Competitor Tracking: Intelligence on company developments, product portfolios, and partnerships.

• Market Opportunity Assessment: Analysis of segments, geographies, and potential business opportunities.

• GTM Strategy and Strategic Consulting: Research support for market entry, expansion, partnerships, and investment planning.

Whether you are evaluating a new CAR T-cell program, expanding manufacturing capacity, assessing a competitor, or identifying potential partners, Towards Healthcare can help connect market evidence with your specific business questions.

Explore CAR T-Cell Therapy Market Intelligence

Access the research, discuss a customized dataset or dashboard, or enquire about the report through the following resources:

• Dashboard access: Towards Healthcare Dashboard

• Sales and customized research enquiries: [email protected] 

Contact Towards Healthcare Research & Consulting to discuss a master dataset, competitive quadrant, customized dashboard, pipeline intelligence, buyer identification, or strategic consulting requirements for the CAR T-cell therapy market.